Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021

HomeEurofins Transplant GenomicsLabs@Home™ Facilitates Outpatient Management of Kidney Transplants During COVID-19

Labs@Home™ Facilitates Outpatient Management of Kidney Transplants During COVID-19

Following the launch in April 2020 of Labs@Home in response to the COVID-19 pandemic began impacting transplant patient care and the world, Transplant Genomics, Inc. announced today the successful growth of TruGraf® driven by adoption of Labs@Home. TruGraf, the only blood test approved by CMS for surveillance to rule out “silent” subclinical acute rejection (subAR) in kidney transplant recipients with stable graft function, has been recognized as crucial to reducing risk in outpatient management after a kidney transplant during COVID-19 in a recently published article from Yale University.

During the COVID-19 pandemic, typical protocols for management of kidney transplant recipients have been difficult to maintain as immunocompromised patients have been urged to stay at home and avoid visiting clinics for routine blood draws or surveillance biopsies. At the same time, clinicians understand that lack of adequate surveillance poses an even greater risk to their patients’ health. Published data informs us that while ~25% of patients undergoing a surveillance biopsy will show signs of rejection roughly three times as many, i.e. ~75%, will have a healthy kidney, which means that with the benefit of hindsight, the invasive tissue biopsy was ultimately unnecessary. With the presence of COVID-19, these risks are further inflated, creating significant unnecessary risks for otherwise healthy patients, making them the highest risk-benefit category of transplant recipients. For these patients with stable graft function, TruGraf, a peripheral blood gene expression test,  provides a liquid biopsy alternative that can reliably rule out whether there is “silent” subclinical acute rejection. Labs@Home enables the necessary blood samples to be collected at home, enabling patients to avoid taking on the added risk of a clinic visit and minimizing the patient load at hospitals where resources are devoted to COVID-19 care.

In one recently published article from Yale School of Medicine, Drs. Shana E. Gleeson, Richard N. Formica, and Ethan P. Marin highlighted this problem accurately, reminding physicians and patients alike the critical benefit and differences in context-of-use between TruGraf and donor-derived cell-free DNA (dd-cfDNA) that “Performance of for-cause biopsies presents another exposure risk, and during this pandemic, the risk-benefit ratio must now incorporate potential exposure to SARS-CoV-2 in the health care facility. As an alternative, practitioners may consider using noninvasive measures of transplant rejection, such as donor-derived cell-free DNA (which may be used in place of for-cause biopsy) or peripheral blood gene expression tests (which may substitute for protocol biopsies).”

Labs@Home is an in-home blood draw service to aid in specimen collection for routine labs and specialty labs directly from a patient’s home. Through our partners at Viracor, clinicians can order and customize remote sample collection to test for a number of infectious diseases, including COVID-19. As part of Eurofins, TGI is actively working to further improve the convenience and quality of service offered to transplant patients, with more announcements expected soon.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy